Molecular Pathology and Genomics



To be a world class division of LMP that provides department, collegiate and national leadership in the pursuit of excellence in molecular pathology and genomic research, education and clinical service

Strategic Intent

To foster a culture of innovation and academic excellence by promoting synergistic collaborations among members of the Division of Molecular Pathology and Genomics



Molecular Pathology and Genomics Membership 

LMP Research Network

Cytogenetics Fellowship
Molecular Genetic Pathology Fellowship

Grand Rounds

September 6, 2017

Todd E. Druley, MD, PhD
Assistant Professor, Pediatrics
Division of Hematology and Oncology
Washington University School of Medicine 

"Improving minimal residual disease detection via error-corrected DNA and RNA sequencing"

 Sponsored by the Division of Molecular Pathology and Genomics

LMP Research Forum

 External Links

Molecular Diagnostics Laboratory

Molecular Diagnostics Laboratory

Anatomic pathologist Andrew Nelson (left), hematopathologist Sophia Yohe, and clinical pathologist Bharat Thyagarajan in the Molecular Diagnostics Laboratory.  The laboratory is at the forefront of the clinical genomics and precision medicine revolution.  Thyagarajan is medical director.

Genomics is helping to transform how cancer is characterized, enabling physicians to select treatments that improve chances of survival and reduce exposure to harmful side effects. Thyagarajan says the MDL focuses on "a narrow set of genes that have been shown to have established clinical relevance." He expects MDL's current panel of some twenty genes in cancer diagnosis to be expanded to a menu of approximately 150 genes distributed across several cancer specific panels within the next six months. "All the action is being directed toward predictive biomarkers, which can influence how the patient is treated." 

What's driving genomics within pathology is the growing demand for more types of molecular-based genomic analyses on specimens and the increased integration of diagnostic technologies. There's an ongoing effort under Thyagarajan, anatomic pathologist Andrew Nelson, hematologist Sophia Yohe and others involved in the department's molecular pathology and genomics initiative to join molecular genetics with cytogenetics and results from flow cytometry and clinical chemistry to get a more complete picture of tumor behavior. Interpretation remains key. 

"The problem that I see routinely is people misunderstanding technological capabilities for clinical interpretive capabilities," Nelson says. "Our ability to interpret the ever-increasing onslaught of data in a clinically meaningful way to predict how the disease will behave is a challenge." One of the ways the challenge can be met is through sound data curation and data sharing by clinical consortia in the U.S. and around the world, Nelson says.
MDL has achieved a major success in its ability to test successfully nearly all cancer specimens it analyzes. Thyagarajan believes community pathologists can benefit from MDL cancer genomics because it
  • uses of minimal amounts of tissue
  • provides integrated diagnostic reports
  • provides expanding gene panels, and
  • has the ability to detect low-level mutations. 

LMP molecular pathologists are happy to consult on cases or help in assessing genomic approaches that might be utilized.


MPG Travel Awards and Great Ideas Awards  

The MPG Travel Awards program is designed to encourage presentations in the area of genomics at national/international meetings such as (but not limited to) ASHG, AMP, ACMG and ACLPS that would enhance the visibility of the Division of Molecular Pathology and Genomics.  

Applications can be submitted on an ongoing basis and applicants will receive a decision within 2 weeks of submission of an application.  The application form can be downloaded here.

The MPG Great Ideas Awards program is open to MPG members, trainees, and research lab staff.  The due date for applications is June 14th.



Recent MPG Faculty Publications

Rashidi A, Nelson AC, Linden MA, Weisdorf DJ, Dolan MM, Ustun C. Genomics of clonal evolution in a case of essential thrombocythemia. Leuk Lymphoma. 2017 Jun 11:1-4. doi: 10.1080/10428194.2017.1337113. [Epub ahead of print] PMID: 28604261

Lou E, D'Souza D, Nelson AC. Therapeutic Response of Metastatic Colorectal Cancer Harboring a KRAS Missense Mutation After Combination Chemotherapy With the EGFR Inhibitor Panitumumab.J Natl Compr Canc Netw. 2017 Apr;15(4):427-432. PMID:28404754